{"product_id":"passagebio-pestle-analysis","title":"Passage Bio PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political, economic, social, technological, legal, and environmental forces are reshaping Passage Bio’s outlook—our concise PESTLE highlights key external risks and growth drivers to inform smarter strategy and investment decisions; purchase the full, editable report for in-depth analysis, actionable insights, and instant download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFederal Drug Pricing Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act’s drug pricing provisions are reshaping pricing dynamics for gene therapies; although orphan drugs often qualify for exemptions, CMS negotiations and increased transparency pressure could compress prices—Medicare drug price negotiations began in 2024 covering high-spend drugs and may expand to biologics, potentially reducing net prices by an estimated 10–20% over a decade; Passage Bio must track federal rulemaking to assess impacts on CNS gene therapy revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Regulatory Harmonization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing efforts to harmonize FDA and EMA rules—such as the 2023 FDA-EMA pilot on parallel scientific advice covering 60+ rare disease programs—benefit Passage Bio by enabling coordinated global trials and potential simultaneous approvals, shortening commercial timelines from typical 7–10 years; streamlined orphan and PRIME-like pathways can cut regulatory delays by months to years and reduce compliance costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease Policy Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical backing for the Orphan Drug Act continues to undergird biotech; orphan designation still offers a 25% R\u0026amp;D tax credit and 7 years market exclusivity, supporting Passage Bio’s gene therapies.\u003c\/p\u003e\n\u003cp\u003eLate-2025 legislative updates increased priority review vouchers and added targeted incentives for CNS disorders, estimated to raise expected net present value of CNS gene therapies by ~12–18%.\u003c\/p\u003e\n\u003cp\u003eThis regulatory stability enables Passage Bio to plan multi-year R\u0026amp;D budgets—CNS program capex forecasts of $120–180M through pivotal trials gain predictability from these policies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Supply Chain Stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe sourcing of specialized reagents and AAV production components is highly exposed to geopolitical tensions; for example, 35% of key plasmid suppliers and 28% of capsid raw material capacity are concentrated in China and Eastern Europe as of 2025, raising disruption risk.\u003c\/p\u003e\n\u003cp\u003eTrade restrictions or sanctions could delay shipments and increase COGS by an estimated 12–18% for Passage Bio’s manufacturing runs, emphasizing vulnerability to diplomatic shifts.\u003c\/p\u003e\n\u003cp\u003eAnalysts should weigh supplier diversification and regional dual-sourcing—moving to North America\/EU partners could reduce single‑source risk by ~60% and stabilize lead times.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% of key suppliers concentrated in China\/Eastern Europe (2025)\u003c\/li\u003e\n\u003cli\u003ePotential 12–18% COGS increase under trade disruption\u003c\/li\u003e\n\u003cli\u003eDiversification to NA\/EU can cut single‑source risk ~60%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Research Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic investment via NIH and federal agencies underpins early-stage genetic work; NIH awarded roughly $45.5B in 2024, with an estimated $1.2B directed to rare disease research, supporting Passage Bio collaborations and preclinical pipelines.\u003c\/p\u003e\n\u003cp\u003eShifts in federal budget priorities—e.g., increased allocation to infectious disease or oncology—could reduce funding for CNS-focused rare disease programs, affecting partner grants and trial funding for Passage Bio.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNIH total funding 2024: ~$45.5B\u003c\/li\u003e\n\u003cli\u003eEstimated rare disease research share: ~$1.2B (2024)\u003c\/li\u003e\n\u003cli\u003eBudget shifts to infectious disease\/oncology risk diverting CNS funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech outlook: Medicare cuts, FDA‑EMA harmony, CNS NPV boost vs. supply‑chain cost risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe IRA-driven Medicare negotiations (started 2024) could cut biologic net prices 10–20% over a decade; FDA‑EMA harmonization (2023 pilot) and late‑2025 CNS incentives raise NPV of CNS gene therapies ~12–18%; supply-chain concentration (35% suppliers in China\/E. Europe) risks 12–18% COGS hikes; NIH funding 2024 ~$45.5B with ~$1.2B for rare disease.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare negotiations\u003c\/td\u003e\n\u003ctd\u003e10–20% price cut (10y)\u003c\/td\u003e\n\u003ctd\u003eRevenue risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA‑EMA harmonization\u003c\/td\u003e\n\u003ctd\u003eParallel advice pilot (60+ programs)\u003c\/td\u003e\n\u003ctd\u003eFaster approvals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS incentives\u003c\/td\u003e\n\u003ctd\u003eNPV +12–18%\u003c\/td\u003e\n\u003ctd\u003eHigher valuation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier concentration\u003c\/td\u003e\n\u003ctd\u003e35% in CN\/EE (2025)\u003c\/td\u003e\n\u003ctd\u003eCOGS +12–18% risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH funding\u003c\/td\u003e\n\u003ctd\u003e$45.5B total; $1.2B rare disease (2024)\u003c\/td\u003e\n\u003ctd\u003ePreclinical support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Passage Bio across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to identify threats and opportunities, support strategic planning, and enhance investor confidence for executives, consultants, and entrepreneurs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, PESTLE-organized summary of Passage Bio that’s presentation-ready and easily shareable, helping teams quickly assess external risks, regulatory landscape, and market positioning for faster, aligned decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Market Accessibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of end-2025, rising cost of capital pressures clinical-stage biotechs: average biotech equity risk premium widened to ~8.2% and median biotech convertible issuance yields rose to ~9.5%, squeezing Passage Bio’s funding options for late-stage trials.\u003c\/p\u003e\n\u003cp\u003ePassage Bio’s ability to raise equity hinges on investor appetite for gene therapy; 2025 biotech IPO proceeds fell 42% YoY, reducing dry powder for high-risk assets.\u003c\/p\u003e\n\u003cp\u003eInterest rate volatility—U.S. 10-year at ~4.1% in Dec 2025—directly raises discount rates used in DCFs for pre-revenue firms, materially lowering present valuations and increasing required funding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Reimbursement Frameworks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe high upfront cost of gene therapies, often exceeding 1–2 million dollars per patient, has driven payers toward value- or outcomes-based reimbursement; by 2024 over 30% of US payers reported piloting such models for cell\/gene therapies. Payers now demand long-term efficacy data—often 5–10 year follow-up—before accepting multi-million-dollar one-time prices. Passage Bio must structure contracts, risk-sharing and real-world evidence generation to secure access and sustainable revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Cost Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation in specialized labor and lab supplies raised biotech baseline burn rates; US lab reagent prices rose about 8–12% in 2024 and skilled biotech wages grew ~6% year-over-year, pressuring Passage Bio’s 2025 operating budget.\u003c\/p\u003e\n\u003cp\u003eEfficient capital allocation and tighter R\u0026amp;D oversight are essential as Passage Bio reported cash burn near $80–95M annually in recent 2024–2025 guidance ranges, making expense management critical.\u003c\/p\u003e\n\u003cp\u003eInvestors monitor how Passage Bio optimizes facilities, headcount, and outsourcing to extend its cash runway beyond the roughly 1.5–2.0 years implied by late-2024 cash balances of about $150–180M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic M\u0026amp;A Landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsolidation in gene therapy has accelerated—big pharma deal value hit $35.4B in 2024 with several high-profile acquisitions—offering Passage Bio clearer exit\/partner routes to commercialize CNS assets.\u003c\/p\u003e\n\u003cp\u003eFavorable M\u0026amp;A conditions (low rates, strong biotech dry powder—estimated $300B in 2024) can provide infrastructure and global reach for Passage Bio; a cooled M\u0026amp;A market would likely push the company toward more dilutive equity raises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 gene therapy deal value: $35.4B\u003c\/li\u003e\n\u003cli\u003eBiotech dry powder (2024): ~$300B\u003c\/li\u003e\n\u003cli\u003eDownside: cooled M\u0026amp;A → increased dilutive financing risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Currency Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs Passage Bio expands into Europe and Asia, currency volatility poses earnings risk; a 10% dollar appreciation could reduce foreign revenue translated to USD by similar magnitude, affecting margins during commercialization.\u003c\/p\u003e\n\u003cp\u003eHedging is essential—biotech peers often hedge 50–80% of forecasted FX exposure; Passage Bio would need robust FX strategies to shield launch revenues.\u003c\/p\u003e\n\u003cp\u003eEconomic instability in key markets (Euro area GDP growth 0.5% in 2024; China growth ~5.2% in 2024) may limit payer willingness to fund premium gene therapies, pressuring uptake and pricing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e10% USD rise can cut translated revenues ~10%\u003c\/li\u003e\n\u003cli\u003eIndustry hedging typically 50–80% of exposure\u003c\/li\u003e\n\u003cli\u003eEuro area growth 0.5% (2024), China ~5.2% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio faces tight runway and funding pressure as rates rise, payers demand outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising cost of capital, higher burn (~$80–95M\/year) and cash runway (~1.5–2.0 years on $150–180M) constrain Passage Bio’s funding; 2024 biotech dry powder ~$300B but 2025 IPO proceeds fell 42% YoY; US 10yr ~4.1% (Dec 2025) raises discount rates; payers push outcomes-based pricing (30% piloting in 2024) and long-term data requirements.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual cash burn\u003c\/td\u003e\n\u003ctd\u003e$80–95M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate‑2024 cash\u003c\/td\u003e\n\u003ctd\u003e$150–180M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003e1.5–2.0 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech dry powder (2024)\u003c\/td\u003e\n\u003ctd\u003e$300B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGene therapy deal value (2024)\u003c\/td\u003e\n\u003ctd\u003e$35.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS 10yr (Dec 2025)\u003c\/td\u003e\n\u003ctd\u003e~4.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers piloting outcomes‑based (2024)\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003ePassage Bio PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Passage Bio PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use with no placeholders or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752106013049,"sku":"passagebio-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/passagebio-pestle-analysis.png?v=1772237678","url":"https:\/\/matrixbcg.com\/products\/passagebio-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}